PE Tech Report


Like this article?

Sign up to our free newsletter

Pharmaceutical start-up takes GBP830,000 in equity funding

Small Pharma, a London-based pharmaceutical startup, has raised GBP830,000, supplemented by a GBP140,000 grant from Innovate UK, to support the development of a rapid-acting drug for patients experiencing severe depression.

The round was led by Chris Torrance, co-founder of Horizon Discovery and PhoreMost, with the Angel CoFund, pharma sector experts and investors Steve Harris, David Ebsworth and Peter Keen, and Secret Escapes co-founder Tom Valentine, also participating.
The investors were joined by 63 additional angels, following a campaign on SyndicateRoom, an angel investing platform.
Torrance has joined the board of Small Pharma, alongside Harris who has sat on the board since November 2015, and is now becoming chairman of the two year-old preclinical biotech. Harris’ board experience includes Skyephama, now merged with Vectura, and Cyprotex, recently acquired by Evotec.  
Small Pharma, founded in 2015 by Peter Rands, focuses on low-cost pharmaceutical product development and has a unique model for selecting and executing projects centred on detailed intellectual property (IP) strategy. The funding will support Small Pharma’s latest project as it develops an antidepressant based on a derivative of ketamine. With an estimated 615 million people suffering from depression and/or anxiety globally, many remain severely undertreated.
The funding will be used to formulate the company’s novel drug product and prepare for proof-of-concept clinical trials.
Rands says: “We are extremely excited to team up with a fantastic set of investors, enabling us to take this project further over the next two years. Depression remains severely undertreated, and with these funds in place we can move forward with a focus on developing our drug candidate to help address the unmet needs of patients with depression.”
Torrance says: “Developing drugs of this nature has to be a priority. Current antidepressants typically take six to twelve weeks before a response is established. A fast acting drug, with a novel yet proven mechanism with reduced side-effects would be transformative in bridging this treatment gap.”
Tim Mills, investment director at the Angel CoFund, says: “The negative impact of acute depression has long been recognised, but to-date the treatment options open to clinicians have been extremely limited. The focus on this major but unaddressed area promises to bring relief to many. We’re extremely proud to be backing Small Pharma as it progresses its latest project that will hopefully change the treatment of depression for millions of people.”

Like this article? Sign up to our free newsletter